Functional Role of VCAM-1 Targeted Flavonoid-Loaded Lipid Nanoemulsions in Reducing Endothelium Inflammation
Total Page:16
File Type:pdf, Size:1020Kb
pharmaceutics Article Functional Role of VCAM-1 Targeted Flavonoid-Loaded Lipid Nanoemulsions in Reducing Endothelium Inflammation Elena Valeria Fuior 1, Mariana Deleanu 1,2, Cristina Ana Constantinescu 1,3, Daniela Rebleanu 1, Geanina Voicu 1, Maya Simionescu 1 and Manuela Calin 1,* 1 Institute of Cellular Biology and Pathology “Nicolae Simionescu”, 050568 Bucharest, Romania 2 Faculty of Biotechnologies, University of Agronomic Sciences and Veterinary Medicine (UASVM), 011464 Bucharest, Romania 3 Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine (UASVM), 050097 Bucharest, Romania * Correspondence: [email protected]; Tel.: +40-21-319-45-18; Fax: +40-21-319-45-19 Received: 30 June 2019; Accepted: 1 August 2019; Published: 3 August 2019 Abstract: Citrus flavonoids have well-documented protective effects on cardiovascular system, but the poor water solubility and reduced bioavailability restrict their therapeutic use. We aimed to overcome these limitations and encapsulated naringenin and hesperetin into lipid nanoemulsions (LNs), targeted to vascular cell adhesion molecule-1 (VCAM-1), which is expressed on activated endothelial cells (ECs). LNs were characterized by a hydrodynamic size of ~200 nm, negative zeta potential, an encapsulation efficiency of flavonoids higher than 80%, good in vitro stability and steady release of the cargo. The LNs were neither cytotoxic to human ECs line EA.hy926, nor provoked in vitro lysis of murine erithrocytes. Then, we tested whether these nanoformulations reduce tumor necrosis factor-alpha (TNF-α) induced EC-activation. We found that flavonoid-loaded LNs, either non-targeted or targeted to the endothelium, were taken up by the EA.hy926 cells in a dose-dependent manner, but dependent on TNF-α only in the case of endothelium-targeted LNs. Moreover, these nanoparticles inhibited both the adhesion and transmigration of THP-1 monocytes on/through activated ECs, by mechanisms involving a reduced expression of the pro-inflammatory chemokine monocyte chemotactic protein 1 (MCP-1) and diminished nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Keywords: cell-targeting peptide; naringenin; hesperetin; endothelium; lipid nanoemulsions; nanoparticle 1. Introduction Naringenin and hesperetin, the main citrus flavonoids, either in their free form or as the corresponding naturally occurring glycosides (Table1), are intensely investigated recently for their therapeutic potential in atherosclerosis and type II diabetes, two of the dreadful pandemics of the developed society. Citrus flavonoids exert a large spectrum of activities such as anti-oxidant, anti-inflammatory, glucose- and lipid-lowering and improve the metabolic parameters: they correct dyslipidemia, increase glucose tolerance and insulin sensitivity, diminish the inflammation and the accumulation of adipose tissue [1,2]. A series of in vitro and in vivo studies indicated that adhesion of monocytes to endothelial cells, an early pro-inflammatory step in atherogenesis, is reduced by the treatment with citrus flavanones via the decreased expression of cell adhesion molecules (i.e., vascular cell adhesion molecule-1 (VCAM-1), intercellular Adhesion Molecule 1 (ICAM-1) and E-selectin) and pro-inflammatory Pharmaceutics 2019, 11, 391; doi:10.3390/pharmaceutics11080391 www.mdpi.com/journal/pharmaceutics Pharmaceutics 2019, 11, 391 2 of 19 cytokines (such as fractalkine also known as chemokine (C-X3-C motif) ligand 1 (CX3CL1), monocyte chemotactic protein 1 (MCP-1) and regulated on activation, normal T cell expressed and secreted (RANTES) [3–5], mediated at least partially through the diminished nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription factor [6]. Pharmaceutics 2019, 11, x Pharmaceutics 2019, 11, x 2 of 19 2 of 19 Table 1. Biochemicalcytokines details (such as offractalkine flavonoids also knowncytokines as chemokine(such incorporated as fractalkine (C-X3-C alsomotif) known ligand into as 1 chemokine (CX3CL1), nanoemulsions (C-X3-Cmonocyte motif) ligand 1 (chemical (CX3CL1), monocyte structure, chemotactic protein 1 (MCP-1) andchemotactic regulated proteinon activation, 1 (MCP-1) normal and T regulated cell expressed on ac tivation,and secreted normal T cell expressed and secreted International Union of(RANTES) Pure [3–5], and mediated Applied at least(RANTES) partially Chemistry through [3–5], mediated the diminished (IUPAC) at least nuclear partially name, translocation through the Chemical of diminished nuclear nuclear Abstracts translocation of Service nuclear (CAS) factor kappa-light-chain-enhancer factorof activated kappa-light-chain-enhancer B cells (NF-κB) transcription of activated factor B [6]. cells (NF-κB) transcription factor [6]. identifier (ID), main glycosides and main citrus source). Table 1. Biochemical details of flavonoidsTable 1.incorporated Biochemical into details nanoemulsions of flavonoids (chemical incorporated structure, into nanoemulsions (chemical structure, International Union of Pure and AppliedInternational Chemis tryUnion (IUPAC) of Pure name, and ChemicalApplied ChemisAbstractstry Service(IUPAC) name, Chemical Abstracts Service Flavanone(CAS) identifier (ID), Naringenin main glycosides (CAS)and main identifier citrus (ID),source). main glycosides and main citrus source). Hesperetin Flavanone NaringeninFlavanone NaringeninHesperetin Hesperetin Structure Structure Structure 5,7-Dihydroxy-2-(4-hydroxyphenyl) chroman-4-5,7-Dihydroxy-2-(4-hydroxyphenyl)(S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4- chroman-4- (S)-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4- IUPAC Name IUPAC Name one methoxyphenyl)-4one H-1-benzopyran-4-one methoxyphenyl)-4H-1-benzopyran-4-one 5,7-Dihydroxy-2-(4-hydroxyphenyl)CAS ID 480-41-1 CAS ID 480-41-1(S )-2,3-Dihydro-5,7-dihydroxy-2-(3-hydroxy-4-520-33-2 520-33-2 IUPAC Name Main naringin(naringenin-7-neohesperidoside)Main naringin(naringenin-7-neohesperidoside)hesperidin (hesperetin 7-rutinoside) neohesperidinhesperidin (hesperetin 7-rutinoside) neohesperidin Glycosides narirutinchroman-4-one ((naringenin-7-rutinoside)Glycosides narirutin ((naringenin-7-rutinoside)(hesperetin 7-neohesperidoside)methoxyphenyl)-4 (hesperetin H7-neohesperidoside)-1-benzopyran-4-one Main Citrus Main Citrus grapefruit grapefruit orange orange CAS IDSource 480-41-1Source 520-33-2 The drawbacks that reduce the efficacy of oral administration of citrus flavanones are poor water naringin(naringenin-7-The drawbacks that reduce the efficacy of oral administration of citrus flavanones are poor water solubility (0.214 and 0.273 g/L for solubilitynaringenin (0.214 and, and respectively, 0.273 g/L hesperetinfor naringenin as hesperidinprovided and, respectively, by [7], but (hesperetinhesperetin as provided 7-rutinoside) by [7], but Main Glycosides even lowerneohesperidoside) according to other sources)even andlower narirutin limited according oral bioavailabilityto other sources) [8,9]. and The limited glycosidic oral bioavailability forms of [8,9]. The glycosidic forms of citrus flavonoids are converted bycitrus the intestinal flavonoids microbiota are converted into the by free theneohesperidin aglycones,intestinal microbiota which are intotaken (hesperetin the free aglycones, 7-neohesperidoside) which are taken up by the enterocytes,(naringenin-7-rutinoside) but there areup large by the interind enterocytes,ividual but variations there are in largethe deglycosylation interindividual capacity variations in the deglycosylation capacity [10] which may result in different profiles[10] which of bioavailable may result in flavonoids. different profiles of bioavailable flavonoids. Main Citrus SourceThese limitations call grapefruit upon alternativeThese limitationsformulations call and/or upon deliveryalternative routes formul to ationsimprove and/or the delivery orange routes to improve the pharmacokinetics of these compounds.pharmacokinetics One successful of thesestrategy compounds. was the complexation One successful of naringeninstrategy was the complexation of naringenin with β-cyclodextrin, which augmentedwith β -cyclodextrin,its solubility 400-fold,which augmented a circumstance its solubility that subsequently 400-fold, a circumstance that subsequently brought about a ~15-fold increase inbrought flavonoid about plasma a ~15-fold concentration increase inand flavonoid improved plasma hypolipemic concentration and and improved hypolipemic and hypoglycemic effects as comparedhypoglycemic to the free subs effectstance asorally compared administered to the free to Sprague-Dawley substance orally ratsadministered to Sprague-Dawley rats The drawbacks that[11]. reduce Oral administration the e offfi naringenin-loadedcacy[11]. Oral of administration oral liposomes administration toof Kunmingnaringenin-loaded mice increased liposomes of ~14-fold citrus to Kunming flavanones mice increased ~14-fold are poor water naringenin bioavailability, with a naringeninpredominant bioavailability, hepatic distribution with a predominant[12]. Naringenin hepatic incorporated distribution [12]. Naringenin incorporated solubility (0.214 and 0.273into gchitosan/Lfor core-shell naringenin nanoparticlesinto coated chitosan and, with core-shell alginate respectively, nanoparticles proved non-toxic coated and with hesperetin efficiently alginate reduced proved non-toxic as provided and efficiently reduced by [7], but even hyperglycemia in streptozotocin-inducedhyperglycemia diabetic in rats streptozotocin-induced upon oral